Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $35.0 million.

  • Ovid Therapeutics' Non-Current Assets fell 489.59% to $35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.3 million, marking a year-over-year decrease of 311.77%. This contributed to the annual value of $36.2 million for FY2024, which is 522.23% up from last year.
  • Per Ovid Therapeutics' latest filing, its Non-Current Assets stood at $35.0 million for Q3 2025, which was down 489.59% from $35.3 million recorded in Q2 2025.
  • In the past 5 years, Ovid Therapeutics' Non-Current Assets ranged from a high of $38.4 million in Q1 2024 and a low of $793980.0 during Q1 2021
  • In the last 5 years, Ovid Therapeutics' Non-Current Assets had a median value of $33.3 million in 2023 and averaged $25.3 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 1945.25% in 2021, then skyrocketed by 254602.22% in 2022.
  • Over the past 5 years, Ovid Therapeutics' Non-Current Assets (Quarter) stood at $4.1 million in 2021, then surged by 487.49% to $23.9 million in 2022, then surged by 44.14% to $34.4 million in 2023, then grew by 5.22% to $36.2 million in 2024, then fell by 3.32% to $35.0 million in 2025.
  • Its Non-Current Assets was $35.0 million in Q3 2025, compared to $35.3 million in Q2 2025 and $35.7 million in Q1 2025.